Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares, par value NIS 1.00, of Sol-Gel Technologies Ltd., a company organized under the laws of the State of Israel, and further agree that this Joint Filing Agreement be included as Exhibit 1 to such Schedule 13G. In evidence thereof, the undersigned hereby execute this agreement this 27th day of October, 2026.
| Trails Edge Capital Partners, LP | ||
| By: Trails Edge Capital Partners, LLC, its general partner | ||
| By: | /s/ Ortav Yehudai | |
| Name: | Ortav Yehudai | |
| Title: | Chief Investment Officer | |
| Trails Edge Biotechnology Master Fund, LP | ||
| By: Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP | ||
| By: Trails Edge GP, LLC, its general partner | ||
| By: | /s/ Ortav Yehudai | |
| Name: | Ortav Yehudai | |
| Title: | Chief Investment Officer | |
| /s/ Ortav Yehudai | |
| Ortav Yehudai |